Closely-held Starton Therapeutics has announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance (NOA) for its U.S. patent application covering the company’s continuous delivery lenalidomide program, STAR-LLD. The NOA significantly broadens the scope of Starton’s proprietary drug delivery system to include transdermal delivery.
With the new patent’s term extending to 2040, Starton will retain full global ownership. The company was previously granted a U.S. patent covering drug delivery systems utilizing parenteral delivery via subcutaneous infusion.
“We are delighted to receive this notice from the USPTO, further expanding the protection of our continuous delivery lenalidomide program,” said Pedro Lichtinger, chairman and CEO of Starton.
“The transdermal delivery system that is the subject of the allowed patent application demonstrates our unique approach to lowering drug exposure and area-under-the-curve to potentially improve efficacy and safety, and demonstrate superiority,” he added.
